Abstract:OBJECTIVE:To investigate the dynamic quantitative changes in expression of hepatitis B virus (HBV) surface antigen (HBsAg) that occurs during the natural recovery course and the short-term antivirus treatment period of patients suffering from flares in chronic hepatitis B (CHB).METHODS:CHB patients presenting for treatment of flare-ups were randomly assigned to receive treatment with Entecavir antiviral (group A, n = 39) or to naturally resolve the acute condition (group B, n = 22). All patients MELD scores were calculated and HBsAg levels and HBV DNA loads were measured upon admission (baseline), at worst-condition stage, and end of treatment/flare-up (discharge). Pairwise comparisons of intergroup differences were made to evaluate the change in the three disease parameters over time in response to the management approach.RESULTS:The levels of HBsAg were not significantly different between the two groups at baseline, worst-condition stage and discharge (group A: (3.68+/-0.45), (3.84+/-0.19) and (3.69+/-0.58) log10 cut-off index (COI) respectively; group B: (3.59+/-0.54), (3.47+/-0.76) and (3.43+/-0.68) log10 COI respectively; all P more than 0.05). However, the HBV DNA loads were significantly lower in group A than in group B at the worst-condition stage and at discharge (all P less than 0.05). In group A, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant. Also in group A, the HBV DNA load showed a gradually decreasing trend over time (baseline more than worst-condition stage more than discharge, all P less than 0.05). No significant differences were observed over time in the HBsAg levels of group A. In group B, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant (P = 0.619). Also in group B, the HBV DNA loads were significantly higher at baseline and worst-condition stage than at discharge (P = 0.000 and P = 0.003 respectively), but the difference between baseline and worst-condition stage was not significant. Finally, no significant differences were observed over time in the HBsAg levels of group B.CONCLUSION:Natural recovery from an acute flare-up of CHB is not accompanied by a change in HBsAg levels. In addition, short-term antiviral treatment to resolve the flare-up has no influence on HBsAg level.

Hepatitis B Surface Antigen Seroclearance In Patients With Chronic Hepatitis B Infection: A Clinical Study

HBcrAg, Pg RNA and HBsAg Dynamically Supervise the Seroconversion of HBsAg with Anti-Viral Therapy "loss of HBsAg" Maybe Not a Good End-Point of Anti-Viral Therapy

Analysis on Clinical Features and Immunity in Chronic Hepatitis B Virus Infected Patients with Low-Level Hbsag

[Dynamic Change of Hepatitis B Surface Antigen Expression in Chronic Hepatitis B Patients During the Natural Recovery Course and the Short-Term Antivirus Treatment].

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta‐analysis

Hepatitis B surface antigen (HBsAg) glycan isomer is predictive of HBsAg seroclearance in patients with chronic hepatitis B

Recurrence and Influencing Factors of Hepatitis B Surface Antigen Seroclearance Induced by Peginterferon Alpha-Based Regimens

HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma

Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B

Role of Hepatitis B Surface Antibody in Seroreversion of Hepatitis B Surface Antigen in Patients Achieving Hepatitis B Surface Antigen Loss with Pegylated Interferon‐Based Therapy

Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B

Response to Chen and Liaw

A Cohort Study on the Epidemiological Characteristics of HBeAg Sero-Clearance in HBeAg Positive Chronic Hepatitis B Patients in Jiangsu Province from 2012 to 2014

Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record

Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up

A nation‐wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan

Favourable Prognosis of Patients with Untreated HBeAg-Negative Chronic Hepatitis B Virus Infection with HBsAg < 100 IU/mL.